Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639846 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
A Phase 2 study, sponsored by C.T. Development America.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01639846: Completed Phase 2 study, sponsored by C.T. Development America.
NCT01639846 is a Phase 2 study that has completed, run by C.T. Development America. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01639846, a Phase 2 study, has completed, sponsored by C.T. Development America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis
Primary Outcome
Ocular itching at defined timepoints up to 2 weeks
Interventions
- DRUG RX-10045
- DRUG Vehicle for RX-10045 arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01639846 record still lists
NCT01639846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which RX-10045 is the first listed.
NCT01639846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01639846 about?
NCT01639846 is a clinical study titled "Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis". To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis
What is the current status of trial NCT01639846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01639846?
The interventions under investigation include: RX-10045 (DRUG), Vehicle for RX-10045 arm (DRUG).
Who is sponsoring clinical trial NCT01639846?
This trial is sponsored by C.T. Development America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01639846's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia